FIELD: medicine.
SUBSTANCE: present invention refers to biotechnology and medicine. What is presented is a method for preventing or treating an inflammatory disease, comprising the stages of producing an NR10 antibody having NR10-neutralising activity, and selecting an antibody inhibiting IL-31-dependent cell line growth, and administering the antibody to a patient with an inflammatory disease that is atopic dermatitis, chronic dermatitis, rheumatism or osteoarthritis.
EFFECT: present invention can find further application in the therapy of the inflammatory diseases.
10 cl, 13 dwg, 10 ex
Title | Year | Author | Number |
---|---|---|---|
THERAPEUTIC AGENT FOR ITCHING | 2008 |
|
RU2541780C2 |
THERAPEUTIC AGENT FOR ITCHING | 2008 |
|
RU2596397C2 |
MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
NEUTRALIZING MONOCLONAL HUMAN ANTI-INTERLEUKIN-33 ANTIBODIES | 2014 |
|
RU2709722C1 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
Authors
Dates
2014-04-10—Published
2007-06-08—Filed